The abstract is read at the publisher; the summary is JClub's.
In HPV+ head and neck squamous cell carcinoma cells, cisplatin tolerance relies on PRIMPOL-mediated repriming and RAD51 filament dynamics, unlike HPV- cells.
- Why it matters: HPV+ tumors respond better to cisplatin-based chemoradiation, but the DNA repair wiring behind this difference is unclear, limiting strategies to reduce long-term toxicity.
- What they did: Genome-wide CRISPR screens compared genetic requirements after cisplatin chemoradiation in HPV- versus HPV+ HNSCC, and HPV16 E6/E7 expression recapitulated the HPV+ tolerance phenotype.
- The result: RAD51 unloading factor FIRRM depletion or RAD51 filament stabilization selectively killed HPV+ and HPV oncogene-expressing cells under cisplatin, and PRIMPOL depletion rescued the lethality, revealing a PRIMPOL-linked therapeutic vulnerability.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.